European Pharmaceutical Review
MARCH 4, 2024
Indeed, in 2022, biologics constituted 40 percent of all US Food and Drug Administration (FDA) approved drugs, projecting a compound annual growth rate (CAGR) of 9.5 percent through 2027. The market for biologics The growing interest in biologics resonates with their impressive expansion on the global market.
Blog: Ask a Student Pharmacist
JUNE 21, 2023
Jiashu Xie, PhD eomizowh Wed, 06/21/2023 - 10:11 Expand all + Biography Research Summary Current research in the Pharmacokinetics (PK) lab has focused on profiling the in vitro ADME (absorption, distribution, metabolism, and excretion) and in vivo PK properties of lead compounds from medicinal chemistry efforts.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
ISPE
MARCH 8, 2023
5 , 8 Compounding pharmacies were commonly mentioned as sources of microbial cross-contamination, especially in the US. 9 , 15 This has led to compounding pharmacies completing high-volume activities such as mass repackaging, thereby increasing the risk of cross-contamination. Compounding Pharmacies: Who Is in Charge?”
Pharmaceutical Technology
APRIL 24, 2023
. “Biologics products may contain proteins that control the action of other proteins and cellular processes, genes that control production of vital proteins, modified human hormones, or cells that produce substances that suppress or activate components of the immune system.
Pharmaceutical Technology
JUNE 21, 2023
With this pipeline, Empress hopes to address unmet clinical needs in immune and inflammatory conditions, and metabolic, neurologic, oncologic, and pain disorders. Analysts forecast the biologics market to be worth $120 billion more than small molecules by 2027. Murray KcKinnon, PhD He joined Empress as chief scientific officer.
Expert insights. Personalized for you.
86 
Let's personalize your content